Second pathway for antidepressants: New fluorescent assay reveals TREK1 mechanism

Researchers have developed a unique cell-based fluorescent assay that enabled them to identify a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel. TREK1 could be an important new target for antidepressant drugs.

Read the whole article on Science Daily

More from Science Daily